{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T04:40:52Z","timestamp":1759639252278,"version":"build-2065373602"},"reference-count":58,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000139","name":"U.S. Environmental Protection Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["19-75-20145"],"award-info":[{"award-number":["19-75-20145"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5 T32GM007040"],"award-info":[{"award-number":["5 T32GM007040"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["T32 EX007126"],"award-info":[{"award-number":["T32 EX007126"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - General Subjects"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.bbagen.2019.129507","type":"journal-article","created":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T16:46:22Z","timestamp":1577205982000},"page":"129507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Lyn regulates creatine uptake in an imatinib-resistant CML cell line"],"prefix":"10.1016","volume":"1864","author":[{"given":"Denis O.","family":"Okumu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas J.","family":"Aponte-Collazo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Dewar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan J.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"East","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Tech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian M.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrey P.","family":"Tikunov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekhson","family":"Holmuhamedov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M.","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee M.","family":"Graves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbagen.2019.129507_bb0005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.bbagen.2019.129507_bb0010","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood.V81.1.158.158","article-title":"The ABL-BCR fusion gene is expressed in chronic myeloid leukemia","volume":"81","author":"Melo","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.bbagen.2019.129507_bb0015","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.bbagen.2019.129507_bb0020","first-page":"1735","article-title":"Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells","volume":"53","author":"Evans","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbagen.2019.129507_bb0025","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V90.9.3691","article-title":"The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells","volume":"90","author":"Deininger","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbagen.2019.129507_bb0030","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbagen.2019.129507_bb0035","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbagen.2019.129507_bb0040","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbagen.2019.129507_bb0045","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0165-4608(02)00615-5","article-title":"BCR\/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration","volume":"139","author":"Campbell","year":"2002","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.bbagen.2019.129507_bb0050","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","article-title":"Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification","volume":"95","author":"le Coutre","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbagen.2019.129507_bb0055","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.bbagen.2019.129507_bb0060","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1600-0609.2007.00835.x","article-title":"Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn","volume":"78","author":"Ito","year":"2007","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bbagen.2019.129507_bb0065","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.bbagen.2019.129507_bb0070","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbagen.2019.129507_bb0075","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1476-5381.2009.00345.x","article-title":"Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells","volume":"158","author":"Klawitter","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbagen.2019.129507_bb0080","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1046\/j.1365-2141.2001.02428.x","article-title":"Glucose transport regulation by p210 Bcr-Abl in a chronic myeloid leukaemia model","volume":"112","author":"Bentley","year":"2001","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bbagen.2019.129507_bb0085","doi-asserted-by":"crossref","first-page":"37747","DOI":"10.1074\/jbc.M105796200","article-title":"Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells","volume":"276","author":"Boren","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbagen.2019.129507_bb0090","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1158\/1078-0432.CCR-17-2697","article-title":"Mitochondrial inhibition augments the efficacy of Imatinib by resetting the metabolic phenotype of gastrointestinal stromal tumor","volume":"24","author":"Vitiello","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbagen.2019.129507_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021924","article-title":"Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells","volume":"6","author":"Kluza","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bbagen.2019.129507_bb0100","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/sj.bjc.6604946","article-title":"Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study","volume":"100","author":"Klawitter","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbagen.2019.129507_bb0105","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.1158\/1078-0432.CCR-04-0039","article-title":"Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells","volume":"10","author":"Gottschalk","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbagen.2019.129507_bb0110","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1038\/sj.onc.1208461","article-title":"Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation","volume":"24","author":"Barnes","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.bbagen.2019.129507_bb0115","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1158\/1078-0432.CCR-08-3291","article-title":"Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells","volume":"15","author":"Kominsky","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbagen.2019.129507_bb0120","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbagen.2019.129507_bb0125","doi-asserted-by":"crossref","first-page":"34227","DOI":"10.1074\/jbc.M402290200","article-title":"A Bcr\/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2","volume":"279","author":"Dai","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbagen.2019.129507_bb0130","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/nm1127","article-title":"Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells","volume":"10","author":"Ptasznik","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbagen.2019.129507_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0177871","article-title":"BIRC6 mediates imatinib resistance independently of Mcl-1","volume":"12","author":"Okumu","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bbagen.2019.129507_bb0140","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1124\/mol.110.066258","article-title":"Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia","volume":"78","author":"Zimmerman","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbagen.2019.129507_bb0145","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11306-010-0204-0","article-title":"Metabolic assessment of a novel chronic myelogenous leukemic cell line and an imatinib resistant subline by H NMR spectroscopy","volume":"6","author":"Dewar","year":"2010","journal-title":"Metabolomics"},{"key":"10.1016\/j.bbagen.2019.129507_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066755","article-title":"Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia","volume":"8","author":"Cooper","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbagen.2019.129507_bb0155","first-page":"C708","article-title":"Kinetics of cyclocreatine and Na(+) cotransport in human breast cancer cells: mechanism of activity","volume":"277","author":"Maril","year":"1999","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.bbagen.2019.129507_bb0160","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1152\/physrev.2000.80.3.1107","article-title":"Creatine and creatinine metabolism","volume":"80","author":"Wyss","year":"2000","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bbagen.2019.129507_bb0165","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.cell.2014.12.018","article-title":"Extracellular metabolic energetics can promote cancer progression","volume":"160","author":"Loo","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.bbagen.2019.129507_bb0170","first-page":"3172","article-title":"Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) inhibits growth of a broad spectrum of cancer cells derived from solid tumors","volume":"53","author":"Lillie","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbagen.2019.129507_bb0175","first-page":"C128","article-title":"Creatine uptake, metabolism, and efflux in human monocytes and macrophages","volume":"251","author":"Loike","year":"1986","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.bbagen.2019.129507_bb0180","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/0888-7543(95)80155-F","article-title":"Assignment of the creatine transporter gene (SLC6A8) to human chromosome Xq28 telomeric to G6PD","volume":"25","author":"Gregor","year":"1995","journal-title":"Genomics"},{"key":"10.1016\/j.bbagen.2019.129507_bb0185","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1006\/bbrc.1994.2475","article-title":"The cloning and expression of a human creatine transporter","volume":"204","author":"Sora","year":"1994","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbagen.2019.129507_bb0190","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1476-5381.2012.01975.x","article-title":"The solute carrier 6 family of transporters","volume":"167","author":"Br\u00f6er","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbagen.2019.129507_bb0195","doi-asserted-by":"crossref","first-page":"38177","DOI":"10.1074\/jbc.M111.267682","article-title":"Ouabain binding site in a functioning Na+\/K+ ATPase","volume":"286","author":"Sandtner","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbagen.2019.129507_bb0200","doi-asserted-by":"crossref","first-page":"ra91","DOI":"10.1126\/scisignal.aaa9623","article-title":"Oxidized LDL-bound CD36 recruits an Na+\/K+-ATPase-Lyn complex in macrophages that promotes atherosclerosis","volume":"8","author":"Chen","year":"2015","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bbagen.2019.129507_bb0205","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1167\/iovs.04-0809","article-title":"The influence of SRC-family tyrosine kinases on Na,K-ATPase activity in lens epithelium","volume":"46","author":"Bozulic","year":"2005","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.bbagen.2019.129507_bb0210","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/j.1471-4159.2005.03147.x","article-title":"Novel regulation of Na, K-ATPase by Src tyrosine kinases in cortical neurons","volume":"93","author":"Wang","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbagen.2019.129507_bb0215","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.drudis.2015.07.008","article-title":"Small-molecule kinase inhibitors: an analysis of FDA-approved drugs","volume":"21","author":"Wu","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bbagen.2019.129507_bb0220","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1091\/mbc.10.9.2847","article-title":"Insulin-induced stimulation of Na+,K(+)-ATPase activity in kidney proximal tubule cells depends on phosphorylation of the alpha-subunit at Tyr-10","volume":"10","author":"F\u00e9raille","year":"1999","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.bbagen.2019.129507_bb0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052879","article-title":"The effect of the creatine analogue beta-guanidinopropionic acid on energy metabolism: a systematic review","volume":"8","author":"Oudman","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbagen.2019.129507_bb0230","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1158\/0008-5472.CAN-03-1484","article-title":"Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia","volume":"64","author":"Donato","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbagen.2019.129507_bb0235","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1177\/2472555218773045","article-title":"Application of integrated drug screening\/kinome analysis to identify inhibitors of gemcitabine-resistant pancreatic cancer cell growth","volume":"23","author":"Krulikas","year":"2018","journal-title":"SLAS Discov."},{"key":"10.1016\/j.bbagen.2019.129507_bb0240","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/bjc.2015.86","article-title":"Acquired resistance to EGFR tyrosine kinase inhibitors alters the metabolism of human head and neck squamous carcinoma cells and xenograft tumours","volume":"112","author":"Beloueche-Babari","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbagen.2019.129507_bb0245","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1126\/science.1218595","article-title":"Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation","volume":"336","author":"Jain","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.bbagen.2019.129507_bb0250","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cell.2011.11.050","article-title":"Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis","volume":"148","author":"Zhang","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bbagen.2019.129507_bb0255","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.18632\/oncotarget.23626","article-title":"Metabolomic alterations in invasive ductal carcinoma of breast: a comprehensive metabolomic study using tissue and serum samples","volume":"9","author":"More","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbagen.2019.129507_bb0260","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/nbm.3526","article-title":"CEST-MRI detects metabolite levels altered by breast cancer cell aggressiveness and chemotherapy response","volume":"29","author":"Chan","year":"2016","journal-title":"NMR Biomed."},{"key":"10.1016\/j.bbagen.2019.129507_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043178","article-title":"Phosphocreatine interacts with phospholipids, affects membrane properties and exerts membrane-protective effects","volume":"7","author":"Tokarska-Schlattner","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bbagen.2019.129507_bb0270","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10495-015-1210-5","article-title":"Phosphocreatine protects against LPS-induced human umbilical vein endothelial cell apoptosis by regulating mitochondrial oxidative phosphorylation","volume":"21","author":"Sun","year":"2016","journal-title":"Apoptosis"},{"key":"10.1016\/j.bbagen.2019.129507_bb0275","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s00726-016-2217-0","article-title":"Creatine kinase in cell cycle regulation and cancer","volume":"48","author":"Yan","year":"2016","journal-title":"Amino Acids"},{"key":"10.1016\/j.bbagen.2019.129507_bb0280","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10974-015-9427-z","article-title":"The extended, dynamic mitochondrial reticulum in skeletal muscle and the creatine kinase (CK)\/phosphocreatine (PCr) shuttle are working hand in hand for optimal energy provision","volume":"36","author":"Wallimann","year":"2015","journal-title":"J. Muscle Res. Cell Motil."},{"key":"10.1016\/j.bbagen.2019.129507_bb0285","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nchembio0309-144","article-title":"A pulse at the heart of targeted therapy","volume":"5","author":"Bradner","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbagen.2019.129507_bb0290","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.exphem.2005.05.020","article-title":"Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate","volume":"33","author":"J\u00f8rgensen","year":"2005","journal-title":"Exp. Hematol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - General Subjects"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030441651930296X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030441651930296X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T04:00:28Z","timestamp":1759636828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030441651930296X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S030441651930296X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbagen.2019.129507","relation":{},"ISSN":["0304-4165"],"issn-type":[{"type":"print","value":"0304-4165"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lyn regulates creatine uptake in an imatinib-resistant CML cell line","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - General Subjects","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbagen.2019.129507","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"129507"}}